Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Abemaciclib Neuropharmacokinetics in Diffuse Midline Glioma
NCT05413304Phase 1Active, not recruiting
- Sponsor
- National Cancer Institute
- Start
- Apr 2023
- Primary completion
- Oct 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of abemaciclib in glioma (2 cohorts), sponsored by National Cancer Institute. Primary endpoints: Percentage of Participants Who Have Adequate Intra-tumoral Sampling and Number of Participants Who Experience Any Type Grade 1-5 Adverse Event. Started Apr 2023; status: active, not recruiting.
02
Drugs
abemaciclib
03
Conditions
glioma
Beyond the preview
Go deeper on NCT05413304.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05413304.